Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

Immunity to Cancer documents the proceedings of a conference on ""Immunity to Cancer"" held at Williamsburg, Virginia, September 10-12, 1984. This was the first open conference since the New York Academy of Sciences meeting in 1975 that attempted to address the entire range of topics encompassed by tumor immunology and immunotherapy. The papers presented in this volume were invited from experts in diverse areas of tumor immunology and closely related subjects. There was an attempt to proceed logically from a consideration of the antigenicity of tumors and the use of monoclonal antibodies to examine specific antigens, to a review of regulatory and effector mechanisms. Immunological approaches to therapy were then considered systematically, both for classical modes of immunotherapy and for the newly expanded categories of biological response modifiers or biomodulators. Also included were papers on vaccination against cancer and on the analogy between the strategies for chemotherapy and immunotherapy.

An authoritative work that provides a detailed review of the current status of cancer prevention and control practice and research. This volume is an essential reference guide and tool for primary care physicians, the research community and students. Written as a collaborative work by the faculty of the nationally renowned Cancer Prevention and Control Program at the Arizona Cancer Center, this book brings together the expertise of specialists in the field of cancer prevention and control to provide the medical and research community that does not specialize in this field with insight to the disciplines of cancer prevention and control.

This book brings together the world’s leading authorities on tumor immunology. This book describes the basic immunology principles that form the foundation of understanding how the immune system recognizes and rejects tumor cells. The role of the innate and adaptive immune responses is discussed and the implications of these responses for the design of clinical strategies to combat cancer are illustrated.

This book overviews cancer immunity from broad scientific fields, based on the concept that cancer is a sort of by-product of infection, inflammation, and host immune response. The innate and acquired arms of the immune system mainly participate in tumor immune surveillance, and their activation is critically modulated by the situation of the tumor microenvironment. Many types of immune cells join the formation of the microenvironment. In particular, macrophages and dendritic cells enter the tumor mass to be main players in the inflammatory milieu of tumors. After introducing these topics, the book discusses immunotherapy for cancer patients as an outgrowth of this concept of infection and inflammation. With the contributions of leading scientists actively involved in the field of antitumor immunity study, this book encourages readers to understand the mechanism of general cancers based on inflammation and will facilitate prevention and the development of therapeutics for cancer.

"This book focusing on the immunopathology of cancers is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Readers will find detailed descriptions of the interactions between cancerous cells and various components of the innate and adaptive immune system. The principal focus, however, is very much on clinical aspects, the aim being to educate clinicians in the clinical implications of the latest research and novel developments in the field. In the new edition of this very well received book, first published in 2015, the original chapters have been significantly updated and additional chapters included on, for example, current knowledge on the roles of T-helper cells and NK cells in tumor immunity, the part played by oncoviruses in the development of various cancers, and the applications of fluorescent in situ hybridization, bioluminescence, and cancer molecular and functional imaging"--Publisher's description.